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You are asked to see a 65-year-old man with an asymptomatic high-grade carotid artery stenosis. He is otherwise quite
healthy, is receiving appropriate medical management, and has no contraindications for surgery. You recommend a
carotid endarterectomy (CEA) as the best prophylactic measure against stroke. During the informed consent process, the
patient asks for a specific estimate of the risks. What specific level of risk should you quote to your patient?
A. Mention the Asymptomatic Carotid Surgery Trial (ACST)1 and the Asymptomatic Carotid Arteriosclerosis Study
(ACAS)2 as the “best case scenario” so as not to discourage the patient from undergoing this operation.
B. You don’t like to be pinned down by numbers, so you tell your patient that the risk is “small.”
C. As a result of a recent quality assurance audit, you are aware that your stroke and death rate after CEA in asymptomatic
patients is 7%. You recognize that this is high, but quote this risk to your patient as the “expected local results.”
D. You’re aware that the American Heart Association recommends CEA for high-grade stenoses if the perioperative risk
of stroke or death is <3%.3,4 As a result of your 7% rate, you rethink the utility of CEA in asymptomatic patients in
your hands and refer to him to a colleague.Informed consent can be defined as the “autonomous
authorization of a medical intervention” after the disclo-
sure of all relevant information. The process for informed
consent for a surgical procedure includes three compo-
nents: disclosure, capacity, and voluntariness.5 This case
scenario outlines some of the issues surrounding disclosure
and what information is relevant to the average patient.
When obtaining consent for a surgical intervention, we
often estimate the risk of the various adverse outcomes.
When these risks are small or not of major clinical signifi-
cance, the absolute numbers are less important. However,
in cases such as CEA where the risks associated with death
and stroke can vary, depending on one’s source, the num-
bers a surgeon chooses to disclose are important. One
would expect the average patient to be very interested in
knowing whether the chance of dying or having a stroke
was 3%, 7%, or somewhere in between, beforemaking his or
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1548her decision regarding treatment. Chances of adverse out-
comes need to be sufficiently low for the patient to benefit
from the prophylactic nature of CEA.
These estimates of perioperative risk are exercises in
predicting the future of an individual patient based on what
has happened in the past to a larger group of patients.
Which group of patients does a surgeon draw on to make
this prediction? Randomized controlled trials (RCT) offer
important information, but epidemiologic difficulties arise
when we try to apply RCT data to an individual patient.
These trials have strict inclusion criteria and involve a large
number of patients treated by many practitioners and hos-
pitals. These outcomes may not relate directly to your
patient, but can be helpful in validating a treatment ap-
proach and providing a yardstick for the expected results in
the average patient.
The more relevant group of patients might be those
treated by you at your hospital. Quality assurance is impor-
tant, and as surgeons, we are obligated to review and
honestly evaluate our treatment outcomes. It is easy to
report these results to a patient when they are better than
those in the literature, but what if they are not? A true,
honest appraisal of our outcomes recognizes that bad
outcomes—and good—tend to group together such that
the period of analysis needs to be of sufficient duration to
allow for a robust comparison of our results with those in
the literature. If these results continue to be worse than
those in the literature, we need to be honest with our
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need to be honest with ourselves about the role of this
treatment in our hands.
Many patient and nonpatient-related factors have a role
in determining the outcome of a surgical intervention.
With carotid surgery, nonpatient-related factors are numer-
ous and include surgeon and surgical team experience and
expertise, quality of postoperative care, and the choice
anesthesia, shunting, and patching. As a result, any single-
center experience is a reflection of these factors.When these
factors are managed optimally, outcomes such as those
obtained in the trials and in many superior single-center
series can be achieved. However, can a patient treated by an
individual surgeon expect results similar to those achieved
in a RCT? Probably not. Therefore, it is unethical and
dishonest, as in answer A, to claim these outcomes as being
achievable at your center unless you can support this claim
with your own data.
Option B is obviously wrong because you are not
providing the information the patient requires.
Expected outcomes after an individual patient-
surgeon-operation interaction depend on the specific fea-
tures of that interaction. These features include the experi-
ence and results of the surgeon and the hospital. The most
relevant information to disclose to this patient is the results
of similar patients treated by you at your hospital. So, if one
piece of information is to be disclosed, it should be that
listed in option C.
However, we must be aware of treatment guidelines,
and when our performance falls below that which is sup-
ported by these guidelines, we should reevaluate the role ofthis operation in our practice. For a vascular surgeon to
proceed with CEA knowing that his or her patients suffer
from a 7% stroke and death rate is clearly unethical, is in
contrast to treatment guidelines, and carries significant
medicolegal implications. As a result, option D is the most
ethical choice. Patients do need to know the results of the
“local” experience, but also should be aware of the “aver-
age” outcomes and those associated with the “best-case
scenario.”
This information is relevant and important in the pro-
cess of obtaining informed consent. This patient will only
benefit from CEA if it is performed by a surgeon with very
low perioperative death and stroke rates. Referral to a
colleague is appropriate while you continue to evaluate
your practice and the contributing factors to these out-
comes.
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